+ Resolve Article
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter

+ Translate
+ Subscribe to Site Feed
GeoScience Most Shared ContentMost Shared Content

Phase I-II trial of concomitant continuous carboplatin (CBDCA) infusion and radiotherapy in advanced nonsmall cell lung cancer with evaluation for surgery: final report

, : Phase I-II trial of concomitant continuous carboplatin (CBDCA) infusion and radiotherapy in advanced nonsmall cell lung cancer with evaluation for surgery: final report. International Journal of Radiation Oncology, Biology, Physics 37(1): 93-101

The goal of this trial was to determine the maximum tolerable dose when carboplatin (CBDCA) was administered in continuous infusion concurrently with radiotherapy in patients with nonsmall cell lung cancer. From October 1989 to July 1993, 54 patients were studied (male/female ratio: 44 to 10), median age was 62 years. Two patients had Stage II cancer, 22 had Stage IIIA, 24 had Stage IIIB, and 6 had Stage IV. Carboplatin was given for 96 h, starting at a dose of 30 mg/m2/day: 13 patients received 30 mg/m2/day (group A), 12 patients received 50 mg/m2/day (group B), 12 patients received 70 mg/m2/day (group C), 10 patients received 90 mg/m2/day (group D), and 7 patients 110 mg/m2/day (group E). The radiation dose was 50.40 Gy delivered to the target volume in 5.3 weeks. Fifty-three of 54 patients were evaluable for toxicity and 52 out of 54 for response. Toxicity (Miller score): Myelotoxicity: in groups A and B it was almost absent; in groups C and D it was moderate (leukopenia G1-2: 45.4% patients; trombocytopenia G1-2: 22.7%, G3: 9%; anemia G1-2: 9%); only in group E was it severe (leukopenia G1 and G3 16.6% respectively; trombocytopenia G3: 33.3%, G4: 16.6%; anemia G1-2: 50%). Nephrotoxicity was present only in one patient of group E and was Grade 3. Nausea and vomiting were related to CBDCA dose. One patient in Group E died of intractable toxicity 3 days after the end of infusion; then the study was closed. The limiting toxicity dose was shown to be 110 mg/m2/day given for 96 h. Clinical response rate: Twenty-six of 52 patients had major response, 24 had minor response, and only 2 patients had progression of disease. Twenty-one of 52 tumors were judged resectable: 18 patients had complete tumor resection, 1 had exploratory thoracotomy, and 2 patients refused surgery. Pathological response rate: Five patients had pathologic state T0 or Tis. These results indicate that the maximum tolerable dose of CBDCA infusion for 96 h is 90 mg/m2/day, and this schedule seems to produce an appreciable response rate. Therefore, we have started a Phase II trial, which will permit us to define the true efficacy of this schedule.


PMID: 9054882

Other references

Kumru, O.S.; Bunikis, I.; Sorokina, I.; Bergström, S.; Zückert, W.R., 2011: Specificity and role of the Borrelia burgdorferi CtpA protease in outer membrane protein processing. To further characterize the function of the Borrelia burgdorferi C-terminal protease CtpA, we used site-directed mutagenesis to alter the putative CtpA cleavage site of one of its known substrates, the outer membrane (OM) porin P13. These mutation...

Ranjhan, S.K., 2001: Animal nutrition in the tropics. This book discusses animal nutrition in the tropics. It is divided into 3 parts. The first part discusses the fundamentals of animal nutrition and is divided into 13 chapters: introduction (1); chemical composition of the tropical feeding stuff (2...

Fedorov, V.A., 1997: On the nesting of the little bittern Ixobrychus minutus in the south west of Pskov region.. Russkii Ornitologicheskii Zhurnal Ekspress Vypusk 14: 16-19

Hosni-Ahmed, A.; Sims, M.; Jones, T.S.; Patil, R.; Patil, S.; Abdelsamed, H.; Yates, C.R.; Miller, D.D.; Pfeffer, L.M., 2015: EDL-360: A Potential Novel Antiglioma Agent. NlmCategory="UNASSIGNED">Glioma is a brain tumor that arises from glial cells or glial progenitor cells, and represents 80% of malignant brain tumor incidence in the United States. Glioblastoma multiforme (GBM) is the most aggressive...

Dusautoir, A., 1988: The nasal pyramid: from "classical" anatomy to the tomodensitometric approach. L' Information Dentaire 70(29): 2659-2663

Cameron D.F.; Murray F.; Obstbaum M.; Wyss H., 1985: Testes and testicular interstitial fluid in the diabetic rat. Anatomical Record 211(3): 32A

Anonymous, 2014: PHYSICIAN'S role as a board member. Bulletin - National Tuberculosis Association 37(7): 98 Passim-98 Passim

Dai, J.; Zhu, L.; Wang, G.; Xiang, F.; Qin, Y.; Wang, M.; Yang, M., 2017: Optical Fiber Grating Hydrogen Sensors: A Review. In terms of hydrogen sensing and detection, optical fiber hydrogen sensors have been a research issue due to their intrinsic safety and good anti-electromagnetic interference. Among these sensors, hydrogen sensors consisting of fiber grating coate...

Woessner W.W.; Remenda V.H.; Ingleton R.; Kuhnel V., 1992: Design and installation of small diameter piezometers to characterize flow and transport in Lake Agassiz clay. Pages 292-301 1992

Burdelski, C.; Strauss, C.; Tsourlakis, M.Christina.; Kluth, M.; Hube-Magg, C.; Melling, N.; Lebok, P.; Minner, S.; Koop, C.; Graefen, M.; Heinzer, H.; Wittmer, C.; Krech, T.; Sauter, G.; Wilczak, W.; Simon, R.; Schlomm, T.; Steurer, S., 2016: Overexpression of thymidylate synthase (TYMS) is associated with aggressive tumor features and early PSA recurrence in prostate cancer. Thymidylate synthase (TYMS) plays a role in DNA synthesis and is a target for 5-fluorouracil. In this study TYMS was analyzed by immunohistochemistry on a tissue microarray containing 11,152 prostate cancers. TYMS expression was higher in neoplast...